CSL (OTCMKTS:CSLLY) Stock Rating Upgraded by Royal Bank Of Canada

CSL (OTCMKTS:CSLLY) was upgraded by stock analysts at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a research note issued on Tuesday, Zacks reports.

CSLLY has been the topic of several other reports. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, CSL currently has a consensus rating of “Hold”.

CSL Stock Performance

Shares of CSL stock opened at $30.65 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. CSL has a twelve month low of $16.01 and a twelve month high of $36.28. The business has a 50-day moving average price of $25.97 and a 200 day moving average price of $23.34.

CSL Company Profile

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.